John C Byrd

46PUBLICATIONS
198CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Aug 20, 2026
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Jul 15, 2025
Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung

|Jun 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann, Ronan Swords, Ying Huang

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

|Feb 26, 2025
A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia.

Basil Allen, Daniel Bottomly, Thomas Köhnke

Pageof 8

Frequent Collaborators

10 joint publications

Jeffrey W Tyner

10 joint publications

Alice S Mims

10 joint publications

Shannon McWeeney

8 joint publications

Christopher A Eide